Bioprocess Analytics & Quality Control
Residual Host Cell DNA Quantification
Quantify residual host cell DNA in biologics with validated qPCR and ddPCR workflows, reported per dose or per product mass against WHO and ICH expectations.
What Residual Host Cell DNA Testing Is
Residual host cell DNA (HCD) is DNA from the production cell line that remains in a biologic drug substance or product after purification. Because many cell substrates used for vaccines, monoclonal antibodies, and recombinant DNA products come from tumor sources or carry tumorigenic potential, cell breakdown during manufacturing can release DNA into the product, and that contamination must be measured in both intermediate and final material.
Quantification is typically performed with target-specific primer/probe sets against a host-cell gene, most often by quantitative PCR (qPCR) and increasingly by droplet digital PCR (ddPCR). Sample preparation may include proteinase digestion and/or RNase treatment to release DNA and remove interfering RNA, depending on the product matrix. Results are reported as residual DNA per dose or per product mass, with regulatory thresholds such as the WHO limit of less than 10 ng per dose.
Safety and purity of the drug substance
Residual host cell DNA is an impurity associated with infection and oncogenicity risk, so it must be controlled and monitored to support drug purity and safety.
- Monitored in intermediates and final product
- Supports tumorigenicity and immunomodulation risk assessment
- Relevant across vaccines, mAbs, and gene therapy vectors
Cell substrates across modalities
Programs commonly tested include Vero, E. coli, HEK293/HeLa-based rAAV, lentivirus, and recombinant vaccines or monoclonal antibodies produced in cell culture.
- Vero cell vaccines and recombinant rotavirus vaccine
- E. coli-expressed recombinant proteins
- rAAV and lentiviral gene therapy products
WHO and ICH expectations
WHO guidance sets an acceptable residual host cell DNA level of less than 10 ng per dose, and ICH guidelines require quantitative assays to be validated for precision, accuracy, detection and quantitation limits, linearity, and specificity.
- WHO
- ICH validation parameters for quantitative assays
- Matrix-specific validation at later clinical stages
| Method | What it measures | Advantages | Considerations |
|---|---|---|---|
| PCR quantifies a host target gene by sequence-specific amplification. | Sequence-specific amplification of a host target gene | Detects specific DNA of concern; widely regarded as the gold standard | No signal if the target sequence is absent; matrix-sensitive |
| Droplet digital PCR | Absolute copy number via partitioned PCR reactions | More precise quantification than qPCR | Target sequence must be present; higher cost than qPCR |
| Threshold assay | Total single-stranded DNA via DNA-binding proteins | Detects total residual DNA without knowing the sequence | Cannot check for sequences of interest |
| Staining methods | Total double-stranded DNA via ultrasensitive nucleic acid stains | Sequence-independent total DNA detection | Requires a specialized reader to interpret results |
How an Engagement Works
Each project is scoped around your product matrix, host cell line, and the stage of development, so the workflow below describes the typical path rather than a fixed package.
Target gene selection
We select a host-cell-specific target gene for your production system, such as 23S rRNA for E. coli, beta-actin for Vero cells, or Alu and ribosomal gene repeats for human cell lines, so the assay reports the DNA that actually matters for your host.
Primer and probe design
Primer/probe sets are designed and validated for qPCR or ddPCR, with specificity, linearity, and amplification efficiency checked against your host genomic DNA before samples are run.
Sample preparation
Depending on the matrix, samples may be treated with proteinase digestion and/or RNase treatment to release DNA and remove interfering RNA, or processed by direct lysis or extraction when the product matrix requires it.
Amplification and quantification
PCR or ddPCR amplification is run against a standard curve or droplet readout to quantify residual DNA, with matrix-appropriate controls and spike-recovery checks to confirm accuracy.
Host-specific primer/probe sets
Targets are chosen for your production cell line, for example 23S rRNA for E. coli, beta-actin for Vero, or Alu and 18S rRNA repeats for human cell lines.
- Species-specific detection of defined host sequences
- Validated specificity against host genomic DNA
- Option to pair with total-DNA readouts
qPCR or ddPCR quantification
We run qPCR where sequence-specific, cost-effective detection is the priority, or ddPCR where absolute copy number and tighter precision are needed.
- qPCR with standard-curve quantification
- ddPCR for absolute copy number
- Platform chosen to match matrix and stage
Matrix-appropriate pretreatment
Pretreatment is matched to your matrix, since assays differ in sensitivity to detergents, high salt, ethanol, residual proteins, or organic solvents.
- Proteinase digestion and/or RNase treatment
- Direct lysis or extraction where required
- Spike-recovery checks for accuracy
Typical Project Scope
The table below describes what can be customized case by case. Scope, sample numbers, and validation depth are defined in the project SOW after consultation.
Assay validation follows ICH expectations for quantitative methods, with standard-matrix validation and sample-specific validation performed as products advance to later clinical stages.
| Parameter | Typical project scope | How it is defined | Notes |
|---|---|---|---|
| Host cell line | Vero, E. coli, HEK293/HeLa, or other production substrate | Confirmed from your manufacturing process | Drives target gene selection |
| Target gene | 23S rRNA, beta-actin, Alu repeats, 18S rRNA, or project-specific locus | Selected for host specificity | Validated against host genomic DNA |
| Platform | Chosen for sensitivity and matrix tolerance | ||
| Sample preparation | Proteinase digestion and/or RNase treatment, direct lysis, or extraction | Matched to product matrix | Matrix changes may require re-evaluation |
| Validation depth | Specificity, linearity, accuracy, precision, detection and quantitation limits | Per ICH expectations for quantitative assays | Sample-specific validation at later stages |
| Reporting basis | Residual DNA per dose or per product mass | Agreed in the SOW | Interpreted against WHO |
Deliverables and Documentation
Every project produces a clear, defensible record of what was measured and how. Deliverable content is scoped per project, but the following elements are standard.
We validate DNA assays using a standard matrix and perform the sample-specific validations required for products at later clinical stages, so your residual DNA measurements are accurate and reliable.
Quantitative results
Residual DNA values reported per dose or per product mass, with standard curves, controls, and spike-recovery data supporting each run.
- Per-dose or per-mass reporting
- Standard curve and control data
- Spike-recovery accuracy checks
Assay documentation
Documentation of target gene selection, primer/probe sequences and validation, sample preparation, and platform parameters for your records.
- Target and primer/probe details
- Sample preparation records
- Platform and analysis parameters
Regulatory-ready reporting
Results interpreted against applicable limits, with validation summaries aligned to ICH expectations for quantitative assays.
- WHO
- ICH-aligned validation summary
- Support for quality and filing review
Assay Validation and Quality
ICH guidelines state that all quantitative assays require validation for precision, accuracy, detection limits, quantitation limits, linearity, and specificity. We apply that framework to residual host cell DNA methods so results hold up to regulatory scrutiny.
Because qPCR is sensitive to matrix interference, sample pretreatment and matrix suitability are treated as part of the method, not an afterthought. Changes in the purification process can shift the sample matrix and affect assay performance, so we re-evaluate suitability when your process changes.
| Validation parameter | What it confirms | Typical approach | Scope note |
|---|---|---|---|
| Specificity | The assay detects the intended host target | Tested against host genomic DNA and related matrices | Defined per host cell line |
| Accuracy | Recovery of known DNA spikes | Spike-recovery experiments in the sample matrix | Matrix-dependent |
| Precision | Repeatability within and between runs | Intra-assay and inter-assay replicates | Scoped per project |
| Limits and linearity | Detection and quantitation limits, linear range | Standard-curve based determination | Sample-specific validation at later stages |
The initial treatment of your samples plays a crucial role in the accuracy of residual DNA analysis. Assays differ in their sensitivity to residuals such as detergents, high salt concentrations, ethanol, residual proteins, or organic solvents, so choosing the appropriate pretreatment is essential for assay suitability.
Common pretreatments include proteinase digestion, RNase treatment, magnetic beads, column-based nucleic acid binding, and precipitation approaches. We help you pick the pretreatment that fits the assay and matrix you are working with.
Why Work With Us
Residual host cell DNA testing sits at the intersection of molecular assay design, matrix science, and regulatory expectation. We bring all three together so you get numbers you can defend, not just numbers you can report.
From target gene selection through validated reporting, our workflows are built to be transparent about what was measured, how, and against which limit, so your quality and regulatory teams have what they need.
FAQ
Should I use qPCR or ddPCR for residual host cell DNA quantification?
It depends on what you need from the result. qPCR is widely regarded as the gold standard for sequence-specific detection and is cost-effective for pinpointing exact sequences of concern. ddPCR partitions reactions into many droplets for more precise, absolute quantification, but the target sequence must still be present. We help you choose based on your matrix, sensitivity needs, and development stage.
Is proteinase digestion always required before qPCR?
Not necessarily. For protein-based drugs, proteinase K treatment is routinely used to digest high protein concentrations that can inhibit qPCR, and it has also been applied to viral vector samples. However, published work on rAAV has shown that the proteinase digestion step can be dispensable when other sample preparation components are retained, so pretreatment should be evaluated for your specific matrix rather than assumed.
Which host cell DNA target gene should be used?
The target should be specific to your production cell line. Examples reported in the literature include 23S ribosomal RNA gene for E. coli, beta-actin for Vero cells, and Alu repeats or 18S rRNA genes for human cell lines such as HEK293 and HeLa. We select and validate a target that matches your host so the assay reports the DNA that actually matters for your product.
What regulatory limit applies to residual host cell DNA?
The World Health Organization sets an acceptable residual host cell DNA level of less than 10 ng per dose for biological products. Results are typically reported as residual DNA per dose or per product mass so they can be compared directly against that threshold, and assay validation follows ICH expectations for quantitative methods.
Can residual host cell DNA be measured in viral vector products?
Yes. Residual host cell DNA is monitored in rAAV and lentiviral products, where encapsidated host DNA cannot be removed by nuclease treatment or affinity purification alone. Methods reported for these matrices include qPCR against repetitive sequences such as Alu repeats and ddPCR targeting ribosomal RNA genes, with sample preparation adapted to the vector matrix.
How is assay accuracy demonstrated?
Accuracy is typically assessed through spike-recovery experiments, where a known amount of host DNA is added to the sample matrix and the measured recovery is compared to the expected value. This, together with specificity, precision, linearity, and detection and quantitation limits, forms the validation package aligned to ICH expectations for quantitative assays.
References
- Li D, Zhang Q, Liu G, et al. Detection of residual E. coli host cell DNA by 23S ribosomal RNA gene-targeted quantitative polymerase chain reactions. Journal of pharmaceutical and biomedical analysis. 2021;198:114000. View on PubMed
- Varnamkhasti FA, Kia V, Shokri R, et al. Design and development of a simple method for the detection and quantification of residual host cell DNA in recombinant rotavirus vaccine. Molecular and cellular probes. 2021;55:101674. View on PubMed
- Higashiyama K, Yuan Y, Hashiba N, et al. Quantitation of Residual Host Cell DNA in Recombinant Adeno-Associated Virus Using Droplet Digital Polymerase Chain Reaction. Human gene therapy. 2023;34(11-12):578-585. View on PubMed
- Li J, Pan R, Yue F, et al. Evaluation of the Efficacy of the Vaccine Production Process in Removing Residual Host Cell DNA from the Vero Cell Rabies Vaccine. Vaccines. 2024;12(12). View on PubMed
- Wang W, Gao T, Luo J, et al. Size distribution analysis of residual host cell DNA fragments in lentivirus by CGE-LIF. Electrophoresis. 2023;44(3-4):462-471. View on PubMed
- Janc M, Zevnik K, Dolinar A, et al. In-Depth Comparison of Adeno-Associated Virus Containing Fractions after CsCl Ultracentrifugation Gradient Separation. Viruses. 2024;16(8). View on PubMed
Scope Your Residual Host Cell DNA Assay
Tell us your host cell line, product matrix, and development stage, and we will outline a quantification approach matched to your program, from target gene selection through validated reporting.